| Document Date: 2014-11-10 10:17:25
Open Document File Size: 260,96 KBShare Result on Facebook
Country United States / / / Facility University Medical Center Freiburg Dept. / Freiburg University / University Hospital Freiburg / / / IndustryTerm therapy of minimal residual disease / prostate cancer therapy / immobilized metal affinity chromatography / Therapeutics for Prostate Cancer / / MedicalCondition frequent malignant disease / minimal residual disease Market Potential Prostate cancer / PSMA-negative tumors / tumor / human PSMA-expressing prostate cancer / Cancer / PSMA positive cancer / tumors / PSMA expressing prostate cancer / prostate cancers / PSMA expressing prostate carcinoma / insensitive and metastatic disease / PSMA expressing prostate cancers / prostate cancer SCID / PSMA expressing tumors / SCID / prostate cancer / metastases / prostate carcinoma / / MedicalTreatment immunotherapy / cancer therapy / adjuvant therapy / / Organization Freiburg University / U. Wetterauer Department of Urology / African Union / PE40 PBS / Freiburg University Medical Center / / Person Philipp Wolf / / / Position Innovation Responsible Scientist / / Technology antibodies / treating cancer / /
SocialTag |
Anti-PSMA Immunotoxins Novel Targeted Therapeutics for Prostate Cancer Technology The Prostate Specific Membrane Antigen (PSMA) has been proven to be an excellent target for prostate cancer therapy. It is highly expresse